347 related articles for article (PubMed ID: 34871271)
1. Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report.
Wang M; Zhu F; Luo N; Li M; Qi Y; Wang M
Medicine (Baltimore); 2021 Nov; 100(44):e27727. PubMed ID: 34871271
[TBL] [Abstract][Full Text] [Related]
2. Complete remission in leptomeningeal metastasis of NSCLC with rare EGFR-SEPT14 fusion treated with osimertinib combined with intrathecal chemotherapy with pemetrexed.
Zheng S; Li H; Feng J; Jiang C; Lin Y; Xie Y; Yu T; Qian X; Yin Z
Anticancer Drugs; 2022 Jan; 33(1):e795-e798. PubMed ID: 34486539
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy analysis of Osimertinib treatment for a patient with leptomeningeal metastasis of EGFR+ non-small cell lung cancer without the T790M mutation.
Hu X; Chen W; Li X; Zhao C; Zhang C; Xiong F; Wu H
Ann Palliat Med; 2019 Nov; 8(5):525-531. PubMed ID: 31865717
[TBL] [Abstract][Full Text] [Related]
4. EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples.
Rangachari D; To C; Shpilsky JE; VanderLaan PA; Kobayashi SS; Mushajiang M; Lau CJ; Paweletz CP; Oxnard GR; Jänne PA; Costa DB
J Thorac Oncol; 2019 Nov; 14(11):1995-2002. PubMed ID: 31377341
[TBL] [Abstract][Full Text] [Related]
5. An Acquired Epidermal Growth Factor Receptor T790M Mutation after the Addition of Bevacizumab to Preceding Erlotinib Monotherapy in a Lung Cancer Patient with Leptomeningeal Metastases.
Tsuchiya K; Karayama M; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Nakamura Y; Inui N; Suda T
Intern Med; 2018 Dec; 57(23):3423-3427. PubMed ID: 30101917
[TBL] [Abstract][Full Text] [Related]
6. Furmonertinib and intrathecal pemetrexed chemotherapy rechallenges osimertinib-refractory leptomeningeal metastasis in a non-small cell lung cancer patient harboring EGFR20 R776S, C797S, and EGFR21 L858R compound EGFR mutations: a case report.
Jia G; Bashir S; Ye M; Li Y; Lai M; Cai L; Xu M
Anticancer Drugs; 2024 Jul; 35(6):542-547. PubMed ID: 38513197
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors.
Saboundji K; Auliac JB; Pérol M; François G; Janicot H; Marcq M; Dubos-Arvis C; Renault A; Guisier F; Odier L; Gervais R; Chouaïd C
Target Oncol; 2018 Aug; 13(4):501-507. PubMed ID: 30039345
[TBL] [Abstract][Full Text] [Related]
8. Osimertinib combined with bevacizumab for leptomeningeal metastasis from EGFR-mutation non-small cell lung cancer: A phase II single-arm prospective clinical trial.
Lu ZQ; Cai J; Wang X; Wei JP; Zeng ZM; Huang L; Liu AW
Thorac Cancer; 2021 Jan; 12(2):172-180. PubMed ID: 33205587
[TBL] [Abstract][Full Text] [Related]
9. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer.
Papadimitrakopoulou VA; Han JY; Ahn MJ; Ramalingam SS; Delmonte A; Hsia TC; Laskin J; Kim SW; He Y; Tsai CM; Hida T; Maemondo M; Kato T; Jenkins S; Patel S; Huang X; Laus G; Markovets A; Thress KS; Wu YL; Mok T
Cancer; 2020 Jan; 126(2):373-380. PubMed ID: 31769875
[TBL] [Abstract][Full Text] [Related]
11. Prognosticators of osimertinib treatment outcomes in patients with EGFR-mutant non-small cell lung cancer and leptomeningeal metastasis.
Chiang CL; Ho HL; Yeh YC; Lee CC; Huang HC; Shen CI; Luo YH; Chen YM; Chiu CH; Chou TY
J Cancer Res Clin Oncol; 2023 Jan; 149(1):5-14. PubMed ID: 36318332
[TBL] [Abstract][Full Text] [Related]
12. Acquired EML4-ALK fusion and EGFR C797S in cis mutation as resistance mechanisms to osimertinib in a non-small cell lung cancer patient with EGFR L858R/T790M.
Wang LS; Chen SQ; Zhong X; Jiao XD; Liu K; Qin BD; Wu Y; Ling Y; Duan XP; Zang YS
Anticancer Drugs; 2023 Nov; 34(10):1146-1150. PubMed ID: 36728908
[TBL] [Abstract][Full Text] [Related]
13. Combination treatment with bevacizumab plus erlotinib for meningeal carcinomatosis of afatinib-resistant EGFR mutated lung cancer without T790M mutation: a case report.
Chiba S; Akiyama M; Yakuwa K; Sato H; Hirano K; Utsumi Y; Nagashima H; Sugai T; Maemondo M
Ann Palliat Med; 2022 Aug; 11(8):2745-2750. PubMed ID: 34806395
[TBL] [Abstract][Full Text] [Related]
14. Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.
Liu J; Jin B; Su H; Qu X; Liu Y
BMC Cancer; 2019 Jul; 19(1):702. PubMed ID: 31315676
[TBL] [Abstract][Full Text] [Related]
15. A non-small cell lung cancer (NSCLC) patient with leptomeningeal metastasis harboring rare epidermal growth factor receptor (EGFR) mutations G719S and L861Q benefited from doubling dosage of osimertinib: a case report.
Shan CG; Wang H; Lin T; Liu D; Wen L; Chen ZJ; Zhen JJ; Lai MY; Zhang L; Zou X; Hong WP; Cai LB
Ann Palliat Med; 2021 May; 10(5):5897-5901. PubMed ID: 33977730
[TBL] [Abstract][Full Text] [Related]
16. Next Generation Sequencing in the Management of Leptomeningeal Metastases of Non-Small Cell Lung Cancer: A Case Report and Literature Review.
Li S; Ke L; Meng X; Zhou H; Zhang X; Wu H; Yu J; Zhang H
Recent Pat Anticancer Drug Discov; 2021; 16(1):108-116. PubMed ID: 33245275
[TBL] [Abstract][Full Text] [Related]
17. Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.
Liu Y; Li Y; Ou Q; Wu X; Wang X; Shao YW; Ying J
Lung Cancer; 2018 Apr; 118():1-5. PubMed ID: 29571986
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of different platforms in detecting EGFR mutations using cerebrospinal fluid cell-free DNA from non-small-cell lung cancer patients with leptomeningeal metastases.
Chiang CL; Ho HL; Yeh YC; Lee CC; Huang HC; Shen CI; Luo YH; Chen YM; Chiu CH; Chou TY
Thorac Cancer; 2023 May; 14(14):1251-1259. PubMed ID: 36977550
[TBL] [Abstract][Full Text] [Related]
19. Potential benefit of osismertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer.
Yi Y; Cai J; Xu P; Xiong L; Lu Z; Zeng Z; Liu A
J Transl Med; 2022 Mar; 20(1):122. PubMed ID: 35287683
[TBL] [Abstract][Full Text] [Related]
20. Genotyping of Cerebrospinal Fluid Associated With Osimertinib Response and Resistance for Leptomeningeal Metastases in EGFR-Mutated NSCLC.
Zheng MM; Li YS; Tu HY; Jiang BY; Yang JJ; Zhou Q; Xu CR; Yang XR; Wu YL
J Thorac Oncol; 2021 Feb; 16(2):250-258. PubMed ID: 33122107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
